Skip to main content

Aditxt, Inc.

corporate_fare Company Profile

Aditxt, Inc.

ADTX·OTC·Life Sciences·CIK 0001726711

The company, incorporated in Delaware on September 28, 2017, and headquartered in Mountain View, California, focuses on redefining how health innovations are discovered, developed, and deployed. Its mission is to transform a centralized industry into a socially owned and guided ecosystem to advance human well-being by engaging stakeholders in all aspects of innovation. Initially, the company focused on an immune modulation technology called ADI/Adimune, aimed at prolonging and enhancing the life quality of organ transplant patients. Since then, it has expanded its portfolio of innovations and subsidiaries and continues to evaluate various promising health innovations. In January 2023, the subsidiary Adimune™, Inc. was formed to lead the company's immune modulation therapeutic programs. Adimune's proprietary product, Apoptotic DNA Immunotherapy™ (ADI™), uses a novel approach that mimics the body's natural tolerance induction to its own tissues. It consists of two DNA molecules designed to deliver signals to induce tolerance. ADI-100, the first product candidate from the ADI platform, is designed to tolerize against glutamic acid decarboxylase ("GAD"), an antigen implicated in type-1 diabetes (T1D), psoriasis, and many autoimmune diseases of the CNS. ADI-100 has been successfully tested in several preclinical models, including skin grafting, psoriasis, and T1D. All preclinical studies for ADI-100 are complete, providing data supporting its potential effectiveness in restoring durable tolerance, as shown in 10-month studies for preventing and treating T1D in nonclinical animal models.

Aditxt, Inc. (OTC:ADTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 44 items for ADTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Aditxt Reports Severe Financial Distress, Nasdaq Delisting Threat, and Massive Derivative Liabilities in Q1 2026
  • Aditxt Announces 1-for-27 Reverse Stock Split to Meet Nasdaq Listing Requirements
  • Aditxt to Execute 1-for-27 Reverse Stock Split May 18 Amid Delisting Threat
  • Nasdaq Issues Delisting Notice to Aditxt Over Persistent Sub-$1.00 Share Price
  • Aditxt Receives Nasdaq Delisting Notice, Ineligible for Standard Compliance Period Due to Prior Reverse Splits

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.19K
Net Income
-$43.1M
Diluted EPS
-$1153.83
Op. Cash Flow
-$25.69M
Free Cash Flow
-$25.7M
Gross Profit
$268
Operating Income
-$19.57M
Cash & Equivalents
$3.2M
Debt / Equity
0.00×
Net Margin
-13490.28×
Shares Outstanding
411.5K sh
Source: 10-K · filed 2026-03-31 · accession 0001213900-26-037529

No longer listed

ADTX (Aditxt, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed ADTX - Filings & News (Page 2)

ADTX
May 20, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
9
ADTX
May 15, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 14, 2026, 8:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ADTX
May 08, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
9
ADTX
May 08, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 01, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
ADTX
Apr 23, 2026, 4:30 PM EDT
Filing Type: 424B3
Importance Score:
8
ADTX
Apr 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
Apr 10, 2026, 9:49 PM EDT
Filing Type: S-3
Importance Score:
9
ADTX
Apr 07, 2026, 4:02 PM EDT
Filing Type: 8-K/A
Importance Score:
9
ADTX
Apr 03, 2026, 4:37 PM EDT
Filing Type: DEF 14A
Importance Score:
9
ADTX
Apr 02, 2026, 9:23 AM EDT
Source: Wiseek News
Importance Score:
8
ADTX
Apr 02, 2026, 9:13 AM EDT
Filing Type: 8-K
Importance Score:
8
ADTX
Mar 31, 2026, 4:35 PM EDT
Filing Type: 10-K
Importance Score:
9
ADTX
Mar 30, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
ADTX
Mar 27, 2026, 5:02 PM EDT
Filing Type: 424B5
Importance Score:
9
ADTX
Mar 24, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
8
ADTX
Mar 13, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
Mar 13, 2026, 8:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ADTX
Mar 05, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets